L. V. Timchenko
L. V. Timchenko has a total of 231 co-authors. Here are the top co-authors by number of shared publications:
- A. M. Alasheyev
Sverdlovsk Regional Clinical Hospital No. 1
9 shared publications - Nikolay A. Shamalov
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; Federal Center of Brain and Neurotechnologies, FMBA of Russia
9 shared publications - Dina R. Khasanova
Kazan State Medical University
8 shared publications - Evgeny I. Gusev
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; Federal Center of Brain and Neurotechnologies, FMBA of Russia
8 shared publications - Nataliya A. Marskaya
Federal Center for Brain and Neurotechnology, Federal Medical-Biological Agency, Moscow, Russia
8 shared publications - Andrey M. Semenov
Faculty of Economics, Patrice Lumumba Peoples’ Friendship University of Russia (RUDN), Moscow (A.M.S., M.P.S.).
7 shared publications
Latest Publications
- Open Access
- 24 April 2026
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 18 (2) , 36-44
Fortelyzin in the treatment of acute ischemic stroke due to basilar-artery occlusion: data from the observational study FORPI registry
The approach to reperfusion therapy for acute ischemic stroke (AIS) in cases of basilar artery occlusion (BAO) remains a matter of debate. Objective: to assess the safety and efficacy of Fortelyzin in patients with BAO in real-world clinical practice, based on data from the FORPI registry. Material and methods. The FORPI registry is an open-label, prospective, non-interventional observational study of Fortelyzin in patients with ischaemic stroke. An analysis was conducted of the safety and efficacy of Fortelyzin in a group of patients with basilar artery occlusion who underwent intravenous thrombolytic therapy (IVT) and bridging therapy. The safety endpoint was the incidence of symptomatic intracranial haemorrhage (SICH) as defined by ECASS III and SITS-MOST, as well as all-cause mortality at 90 days. The efficacy endpoint was defined as good functional recovery, defined as a score of 0–2 on the modified Rankin Scale (MRS) at 90 days. Results. This analysis included 1910 patients who underwent IVT and 53 patients who underwent bridging therapy. The median National Institutes of Health Stroke Scale (NIHSS) scores at admission were 9 and 12 points, respectively (p = 0.01). SICH incidence (ECASS III criteria) was significantly higher in the bridging therapy group compared to IVT group (6 % vs 1 %, p = 0.01). All-cause mortality at day 90 did not differ significantly between the groups (9 % and 7 %, respectively, p = 0.52). Good functional recovery at day 90 was achieved by 69 % of patients in the IVT group and 60 % of patients in the bridging therapy group (p = 0.31). Conclusion. The use of Fortelyzin in AIS patients with BAO may be considered an effective and safe form of reperfusion therapy, as well as a component of bridging therapy aimed at increasing the number of favorable functional outcomes.
- 24 April 2026
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 18 (2) , 36-44
Open AccessFortelyzin in the treatment of acute ischemic stroke due to basilar-artery occlusion: data from the observational study FORPI registry
The approach to reperfusion therapy for acute ischemic stroke (AIS) in cases of basilar artery occlusion (BAO) remains a matter of debate. Objective: to assess the safety and efficacy of Fortelyzin in patients with BAO in real-world clinical practice, based on data from the FORPI registry. Material and methods. The FORPI registry is an open-label, prospective, non-interventional observational study of Fortelyzin in patients with ischaemic stroke. An analysis was conducted of the safety and efficacy of Fortelyzin in a group of patients with basilar artery occlusion who underwent intravenous thrombolytic therapy (IVT) and bridging therapy. The safety endpoint was the incidence of symptomatic intracranial haemorrhage (SICH) as defined by ECASS III and SITS-MOST, as well as all-cause mortality at 90 days. The efficacy endpoint was defined as good functional recovery, defined as a score of 0–2 on the modified Rankin Scale (MRS) at 90 days. Results. This analysis included 1910 patients who underwent IVT and 53 patients who underwent bridging therapy. The median National Institutes of Health Stroke Scale (NIHSS) scores at admission were 9 and 12 points, respectively (p = 0.01). SICH incidence (ECASS III criteria) was significantly higher in the bridging therapy group compared to IVT group (6 % vs 1 %, p = 0.01). All-cause mortality at day 90 did not differ significantly between the groups (9 % and 7 %, respectively, p = 0.52). Good functional recovery at day 90 was achieved by 69 % of patients in the IVT group and 60 % of patients in the bridging therapy group (p = 0.31). Conclusion. The use of Fortelyzin in AIS patients with BAO may be considered an effective and safe form of reperfusion therapy, as well as a component of bridging therapy aimed at increasing the number of favorable functional outcomes.
- Open Access
- 24 April 2026
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 18 (2) , 45-53
Fortelyzin in the treatment of minor acute ischemic stroke according to a subanalysis of the observational study FORPI registry
The question of whether intravenous thrombolytic therapy (ITT) is appropriate for patients with a minor stroke (NIHSS score < 5) remains a matter of debate. Fortelysin is a thrombolytic agent used to treat ischemic stroke. Objective: to assess the safety and efficacy of Fortelyzin in patients who have suffered a minor stroke in real-world clinical practice, based on data from a subanalysis of the FORPI registry. Material and methods. The FORPI registry is an open-label, prospective, non-interventional, observational study of Fortelyzin in patients with acute ischemic stroke. We analyzed the safety and efficacy of Fortelyzin in a group of patients with minor stroke characterized by an NIHSS < 5. Safety outcomes were the number of symptomatic intracranial hemorrhage (sICH) according to ECASS III and SITS-MOST definitions, as well as all-cause mortality at day 90. The efficacy outcome was a functional independence, defined by modified Rankin scale (mRS) score of 0–2 points at day 90. Results. The analysis included 836 patients with an NIHSS < 5 points. The median age was 64 [56; 72] years, and the median NIHSS score at admission was 4 [3; 4] points. SICH according to ECASS III definition was observed in three patients of 836 (0.4 %), and according to SITS-MOST definition, in four patients of 836 (0.5 %). All-cause mortality at day 90 was 2.2 % (18/836). The proportion of patients with functional independence (mSR of 0–2 points) at day 90 reached in 88 % (737/836) of patients. Conclusion. The FORPI registry provides compelling evidence that early intensive rehabilitation using Fortelyzin is characterised by a high level of safety and efficacy in patients who have suffered a minor stroke.
- 24 April 2026
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 18 (2) , 45-53
Open AccessFortelyzin in the treatment of minor acute ischemic stroke according to a subanalysis of the observational study FORPI registry
The question of whether intravenous thrombolytic therapy (ITT) is appropriate for patients with a minor stroke (NIHSS score < 5) remains a matter of debate. Fortelysin is a thrombolytic agent used to treat ischemic stroke. Objective: to assess the safety and efficacy of Fortelyzin in patients who have suffered a minor stroke in real-world clinical practice, based on data from a subanalysis of the FORPI registry. Material and methods. The FORPI registry is an open-label, prospective, non-interventional, observational study of Fortelyzin in patients with acute ischemic stroke. We analyzed the safety and efficacy of Fortelyzin in a group of patients with minor stroke characterized by an NIHSS < 5. Safety outcomes were the number of symptomatic intracranial hemorrhage (sICH) according to ECASS III and SITS-MOST definitions, as well as all-cause mortality at day 90. The efficacy outcome was a functional independence, defined by modified Rankin scale (mRS) score of 0–2 points at day 90. Results. The analysis included 836 patients with an NIHSS < 5 points. The median age was 64 [56; 72] years, and the median NIHSS score at admission was 4 [3; 4] points. SICH according to ECASS III definition was observed in three patients of 836 (0.4 %), and according to SITS-MOST definition, in four patients of 836 (0.5 %). All-cause mortality at day 90 was 2.2 % (18/836). The proportion of patients with functional independence (mSR of 0–2 points) at day 90 reached in 88 % (737/836) of patients. Conclusion. The FORPI registry provides compelling evidence that early intensive rehabilitation using Fortelyzin is characterised by a high level of safety and efficacy in patients who have suffered a minor stroke.
- 15 April 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (3) , 106-115
Fortelyzin in the treatment of acute ischemic stroke in patients ≥80 years old: data from the observational study FORPI registry
Objective. The aim of this study was to evaluate the safety and efficacy of Fortelyzin in patients ≥80 years with ischemic stroke (IS) in real-world clinical practice using data from the FORPI registry. Material and Methods. Fortelyzin (INN/chemical name — a recombinant protein containing the amino acid sequence of staphylokinase, SuperGene LLC, Moscow, Russia) is a thrombolytic used for acute IS treatment within the first 4.5 hours of symptom onset. The FORPI registry is an open-label, prospective, non-interventional, observational study of Fortelyzin in patients with IS. We analyzed the safety and efficacy outcomes in patients ≥80 years compared with patients <80 years. Safety outcomes included the incidence of symptomatic intracranial hemorrhage (sICH) according to ECASS III and SITS-MOST definitions, as well as all-cause mortality on day 90. The efficacy outcome was a good functional recovery, defined by an mRS score of 0—2 on day 90. Results. 2649 (15%) patients were ≥80 years, and 14 987 (85%) patients were <80 years. The median age in the group of patients ≥80 years was 83 (82—86) years. Patients ≥80 years were characterized by a more complicated medical history and a higher median of NIHSS and mRS score. The sICH rate according to ECASS III definition in patients ≥80 years old was 4.0%, in patients <80 years old — 1.7% (OR 2.42 (1.90—3.07), p<0.001), according to SITS-MOST definition — 3.2% and 1.6%, respectively (OR 2.03 (1.56—2.61), p<0.001); in-hospital all-cause mortality was 17% and 7% (OR 2.76 (2.44—3.11, p<0.001), all-cause mortality on day 90 was 19% and 7% (OR 3.00 (2.67—3.37, p<0.001), respectively. Good functional recovery (mRS 0—2 score) on day 90 was achieved in 43% of patients ≥80 years and 64% in patients <80 years of age (OR 0.42 (0.38—0.46, p<0.001)). Conclusion. FORPI study showed that although the risk of sICH with Fortelyzin is higher in patients ≥80 years than in patients <80 years, it remains low, suggesting that thrombolytic therapy is safe and necessary in these patients.
- 15 April 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (3) , 106-115
Fortelyzin in the treatment of acute ischemic stroke in patients ≥80 years old: data from the observational study FORPI registry
Objective. The aim of this study was to evaluate the safety and efficacy of Fortelyzin in patients ≥80 years with ischemic stroke (IS) in real-world clinical practice using data from the FORPI registry. Material and Methods. Fortelyzin (INN/chemical name — a recombinant protein containing the amino acid sequence of staphylokinase, SuperGene LLC, Moscow, Russia) is a thrombolytic used for acute IS treatment within the first 4.5 hours of symptom onset. The FORPI registry is an open-label, prospective, non-interventional, observational study of Fortelyzin in patients with IS. We analyzed the safety and efficacy outcomes in patients ≥80 years compared with patients <80 years. Safety outcomes included the incidence of symptomatic intracranial hemorrhage (sICH) according to ECASS III and SITS-MOST definitions, as well as all-cause mortality on day 90. The efficacy outcome was a good functional recovery, defined by an mRS score of 0—2 on day 90. Results. 2649 (15%) patients were ≥80 years, and 14 987 (85%) patients were <80 years. The median age in the group of patients ≥80 years was 83 (82—86) years. Patients ≥80 years were characterized by a more complicated medical history and a higher median of NIHSS and mRS score. The sICH rate according to ECASS III definition in patients ≥80 years old was 4.0%, in patients <80 years old — 1.7% (OR 2.42 (1.90—3.07), p<0.001), according to SITS-MOST definition — 3.2% and 1.6%, respectively (OR 2.03 (1.56—2.61), p<0.001); in-hospital all-cause mortality was 17% and 7% (OR 2.76 (2.44—3.11, p<0.001), all-cause mortality on day 90 was 19% and 7% (OR 3.00 (2.67—3.37, p<0.001), respectively. Good functional recovery (mRS 0—2 score) on day 90 was achieved in 43% of patients ≥80 years and 64% in patients <80 years of age (OR 0.42 (0.38—0.46, p<0.001)). Conclusion. FORPI study showed that although the risk of sICH with Fortelyzin is higher in patients ≥80 years than in patients <80 years, it remains low, suggesting that thrombolytic therapy is safe and necessary in these patients.
- 5 March 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (2) , 59-67
Fortelizin in bridging therapy of acute ischemic stroke: data from the observational study FORPI registry
Objective. To evaluate the safety and efficacy of Fortelyzin during bridging therapy (thrombolysis followed by thrombectomy) in real-world clinical practice using data from the FORPI registry. Material and methods. The FORPI registry is an open-label, prospective, non-interventional observational study of Fortelyzin in patients with acute ischemic stroke. In this article we analyzed the safety and efficacy of Fortelyzin in patients undergoing thrombolysis followed by thrombectomy. The safety outcomes were the rate of symptomatic intracranial hemorrhage (sICH) according to ECASS III and SITS-MOST definitions, as well as all-cause mortality on day 90. The efficacy outcome was a good functional recovery, defined by mRS score of 0—2 on day 90. Results. The analysis included 1116 patients undergoing thrombolysis followed by thrombectomy who were enrolled in a registry at 120 medical cites in 55 regions of the Russian Federation. The median patient age was 69 (61—77) years. The median NIHSS score at admission was 15 (12—19) points. The sICH rate according to ECASS III was 13% (144/1116), and according to SITS-MOST was 9% (98/1116). In hospital mortality rate was 27% (301/1116 patients). All-cause mortality on day 90 was 29% (322/1116 patients). Good functional outcome (mRS 0—2) on day 90 was achieved in 38% (422/1116) of patients. Conclusion. This study demonstrates the safety and efficacy of Fortelizin in bridging therapy of acute ischemic stroke in real-world clinical practice.
- 5 March 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (2) , 59-67
Fortelizin in bridging therapy of acute ischemic stroke: data from the observational study FORPI registry
Objective. To evaluate the safety and efficacy of Fortelyzin during bridging therapy (thrombolysis followed by thrombectomy) in real-world clinical practice using data from the FORPI registry. Material and methods. The FORPI registry is an open-label, prospective, non-interventional observational study of Fortelyzin in patients with acute ischemic stroke. In this article we analyzed the safety and efficacy of Fortelyzin in patients undergoing thrombolysis followed by thrombectomy. The safety outcomes were the rate of symptomatic intracranial hemorrhage (sICH) according to ECASS III and SITS-MOST definitions, as well as all-cause mortality on day 90. The efficacy outcome was a good functional recovery, defined by mRS score of 0—2 on day 90. Results. The analysis included 1116 patients undergoing thrombolysis followed by thrombectomy who were enrolled in a registry at 120 medical cites in 55 regions of the Russian Federation. The median patient age was 69 (61—77) years. The median NIHSS score at admission was 15 (12—19) points. The sICH rate according to ECASS III was 13% (144/1116), and according to SITS-MOST was 9% (98/1116). In hospital mortality rate was 27% (301/1116 patients). All-cause mortality on day 90 was 29% (322/1116 patients). Good functional outcome (mRS 0—2) on day 90 was achieved in 38% (422/1116) of patients. Conclusion. This study demonstrates the safety and efficacy of Fortelizin in bridging therapy of acute ischemic stroke in real-world clinical practice.
- 9 February 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (1) , 82-91
Fortelyzin for acute ischaemic stroke treatment in an extended (4.5 to 24 hours from the onset of symptoms) time window: data from the observational study FORPI registry
Objective. To evaluate the safety and efficacy of Fortelyzin thrombolytic drug (non-immunogenic staphylokinase) in AIS patients in an «extended» therapeutic window from 4.5 to 24 h from symptoms’ onset based on data from the FORPI registry. Material and methods. Functional outcomes and the risk of intracranial hemorrhage after thrombolytic therapy (TLT) for acute ischemic stroke (AIS) are known to be directly dependent on the treatment time initiation. Although the most safe and effective time for TLT is the first 4.5 h from symptoms’ onset, a significant proportion of patients are hospitalized beyond this time window. The objective of this study is The FORPI registry is an open-label, prospective, non-interventional observational study of Fortelyzin in AIS patients in real-world clinical practice. A comparative analysis of safety and efficacy outcomes was conducted in groups of patients who received TLT in the first 4.5 h after symptom onset and beyond 4.5 h time window. The safety endpoints were the rate of symptomatic intracranial hemorrhage (sICH) according to ECASS III and SITS-MOST criteria, as well as all-cause mortality at day 90. The efficacy endpoint was good functional recovery, defined by a modified Rankin Scale (mRS) of 0—2 score at day 90. Results. The analysis included 17.636 patients with TLT performed in the first 4.5 h after symptom onset and 358 patients with TLT performed beyond 4.5 h time window (up to 24 hours). In the group of patients with TLT performed in the interval of 4.5—24 hours, there were statistically significantly fewer people over 80 years old (8% vs 16%, p=0.001), and a lower median age (66 vs 68 years, p=0.002) compared with the group of TLT within 4.5 hours. The NIHSS median was slightly higher in the group of patients with TLT performed beyond 4.5 h time window (11 (8—16) vs 11 (8—15), p=0.036). The incidence of sICH (ECASS III) within 4.5 h was 2% compared with 2.5% beyond 4.5 h time window (p=0.454). All-cause mortality at 90 days in the main population was 9%, which is comparable with the mortality rate in the 4.5—24 h group — 7% (p=0.160). Good functional recovery (mSR 0—2) at day 90 was achieved in 61% of patients in the group who received TLT within 4.5 h, compared with 65% of patients who received TLT beyond 4.5 h time window (p=0.227). Conclusion. FORPI registry demonstrates similar data on the safety and efficacy of TLT with Fortelyzin in AIS patients both within 4.5 hours and beyond 4.5 hours from symptoms’ onset.
- 9 February 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (1) , 82-91
Fortelyzin for acute ischaemic stroke treatment in an extended (4.5 to 24 hours from the onset of symptoms) time window: data from the observational study FORPI registry
Objective. To evaluate the safety and efficacy of Fortelyzin thrombolytic drug (non-immunogenic staphylokinase) in AIS patients in an «extended» therapeutic window from 4.5 to 24 h from symptoms’ onset based on data from the FORPI registry. Material and methods. Functional outcomes and the risk of intracranial hemorrhage after thrombolytic therapy (TLT) for acute ischemic stroke (AIS) are known to be directly dependent on the treatment time initiation. Although the most safe and effective time for TLT is the first 4.5 h from symptoms’ onset, a significant proportion of patients are hospitalized beyond this time window. The objective of this study is The FORPI registry is an open-label, prospective, non-interventional observational study of Fortelyzin in AIS patients in real-world clinical practice. A comparative analysis of safety and efficacy outcomes was conducted in groups of patients who received TLT in the first 4.5 h after symptom onset and beyond 4.5 h time window. The safety endpoints were the rate of symptomatic intracranial hemorrhage (sICH) according to ECASS III and SITS-MOST criteria, as well as all-cause mortality at day 90. The efficacy endpoint was good functional recovery, defined by a modified Rankin Scale (mRS) of 0—2 score at day 90. Results. The analysis included 17.636 patients with TLT performed in the first 4.5 h after symptom onset and 358 patients with TLT performed beyond 4.5 h time window (up to 24 hours). In the group of patients with TLT performed in the interval of 4.5—24 hours, there were statistically significantly fewer people over 80 years old (8% vs 16%, p=0.001), and a lower median age (66 vs 68 years, p=0.002) compared with the group of TLT within 4.5 hours. The NIHSS median was slightly higher in the group of patients with TLT performed beyond 4.5 h time window (11 (8—16) vs 11 (8—15), p=0.036). The incidence of sICH (ECASS III) within 4.5 h was 2% compared with 2.5% beyond 4.5 h time window (p=0.454). All-cause mortality at 90 days in the main population was 9%, which is comparable with the mortality rate in the 4.5—24 h group — 7% (p=0.160). Good functional recovery (mSR 0—2) at day 90 was achieved in 61% of patients in the group who received TLT within 4.5 h, compared with 65% of patients who received TLT beyond 4.5 h time window (p=0.227). Conclusion. FORPI registry demonstrates similar data on the safety and efficacy of TLT with Fortelyzin in AIS patients both within 4.5 hours and beyond 4.5 hours from symptoms’ onset.
- 30 December 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (12) , 43-59
Fortelyzin for acute ischaemic stroke treatment: an open, prospective, non-interventional, observational study FORPI registry
Objective. To evaluate safety and efficacy outcomes of Fortelyzin in AIS patients in the FORPI (Fortelyzin Population Investigation) registry. Material and methods. Between March 2021 and October 2024 AIS patients treated with Fortelyzin were enrolled in prospective, open, monitored, observational FORPI registry. Demographics, risk factors, baseline stroke severity, defined by National Institutes of Health Stroke Scale (NIHSS), and onset to treatment time were recorded. Safety outcomes included symptomatic intracerebral haemorrhage (ICH) (according to the ECASS III and SITS-MOST criteria) within 36 h and all-cause mortality on day 90. Efficacy outcome was evaluated as a functional independence defined by modified Rankin scale (mRS score of 0—2) on day 90. Results. A total of 17 636 AIS patients were treated with Fortelyzin in 329 centres participated in the FORPI registry during the study period (median age 68 [60; 75]; 44% women; median baseline NIHSS score: 11 [8;16] points; median onset to treatment time: 2.4 [1.8; 3.1] h. 73% of patients (12947/17 636) received thrombolytic therapy in the first three hours from symptoms onset. The rate of symptomatic ICH according to the ECASS III criteria was 2% [1.8; 2.2] (356/17636), to the SITS-MOST criteria — 2% [1.8; 2.1] (330/17 636). All-cause mortality on day 90 was 9% [8.6; 9.4] (1588/17 636). The number of patients with mRS 0—2 score on day 90 was 61% [60.5; 61.9] (10799/17636). All safety and efficacy outcomes were comparable with FRIDA randomised clinical trial results. Conclusion. The presented data confirm that intravenous thrombolysis with Fortelyzin is safe and effective in routine clinical practice when used within 4.5 h of AIS symptoms onset. These findings should encourage the wider usage of thrombolytic therapy for suitable patients.
- 30 December 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (12) , 43-59
Fortelyzin for acute ischaemic stroke treatment: an open, prospective, non-interventional, observational study FORPI registry
Objective. To evaluate safety and efficacy outcomes of Fortelyzin in AIS patients in the FORPI (Fortelyzin Population Investigation) registry. Material and methods. Between March 2021 and October 2024 AIS patients treated with Fortelyzin were enrolled in prospective, open, monitored, observational FORPI registry. Demographics, risk factors, baseline stroke severity, defined by National Institutes of Health Stroke Scale (NIHSS), and onset to treatment time were recorded. Safety outcomes included symptomatic intracerebral haemorrhage (ICH) (according to the ECASS III and SITS-MOST criteria) within 36 h and all-cause mortality on day 90. Efficacy outcome was evaluated as a functional independence defined by modified Rankin scale (mRS score of 0—2) on day 90. Results. A total of 17 636 AIS patients were treated with Fortelyzin in 329 centres participated in the FORPI registry during the study period (median age 68 [60; 75]; 44% women; median baseline NIHSS score: 11 [8;16] points; median onset to treatment time: 2.4 [1.8; 3.1] h. 73% of patients (12947/17 636) received thrombolytic therapy in the first three hours from symptoms onset. The rate of symptomatic ICH according to the ECASS III criteria was 2% [1.8; 2.2] (356/17636), to the SITS-MOST criteria — 2% [1.8; 2.1] (330/17 636). All-cause mortality on day 90 was 9% [8.6; 9.4] (1588/17 636). The number of patients with mRS 0—2 score on day 90 was 61% [60.5; 61.9] (10799/17636). All safety and efficacy outcomes were comparable with FRIDA randomised clinical trial results. Conclusion. The presented data confirm that intravenous thrombolysis with Fortelyzin is safe and effective in routine clinical practice when used within 4.5 h of AIS symptoms onset. These findings should encourage the wider usage of thrombolytic therapy for suitable patients.
- 30 December 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (12) , 60-67
Therapeutic equivalence of intravenous and intramuscular dosage forms of Cortexin in ischemic strokes
Objective. Study of the therapeutic equivalence of forms for intramuscular and intravenous administration of the drug Cortexin in patients in the acute and early recovery periods of ischemic stroke (IS). Material and methods. A multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted. The study included 490 patients with acute IS, male (54.1%) and female (45.9%) aged from 30 to 80 years (average age 63.97+8.5 years), divided into 2 groups: 1 — main (Cortexin intravenous form, n=246), 2 — comparison (Cortexin intramuscular form, n=244). Patients in both groups received 2 courses of therapy lasting 10 days. In the first course: Group 1 — Cortexin 10 mg IV and placebo IM 2 times a day; Group 2 — Cortexin 10 mg IM and placebo IV 2 times a day. After 10 days, patients in both groups received a second course of therapy with Cortexin 10 mg, IM, 2 times a day, 10 days. The period of active treatment and observation for each patient was 90 days. The evaluation of the effectiveness of the studied Cortexin dosage forms was defined as the proportion of patients who reached 0—2 on the modified Rankin scale (mRS) on the 90th day of the study. Additionally, the dynamics of scores on the Stroke Scale of the National Institute of Health (NIHSS) and the Short Mental Status Assessment Scale (MMSE) were evaluated on the days of active treatment and follow-up. Safety was assessed by the frequency of adverse events (AE). Results. The proportion of patients who reached 0—2 on the mRS scale on day 90 was 93.64% and 86.50% in the groups receiving Cortexin intravenously and intramuscularly, respectively. By the end of the follow-up period, the total score on the NIHSS scale decreased by 3.93 and 3.72, respectively, in both groups. According to the MMSE scale, by the day of completion of the study, the overall dynamics of the average score in group 1 was 4.11, in the comparison group 3.88 (p=0.249). The study showed the comparable safety of the two dosage forms of Cortexin. In the main group 1, 74 AES were registered in 60 patients, in the comparison group — 51 AES in 41 people, the number of cases did not differ between the groups (p>0.05). Conclusion. The intravenous form of Cortexin administration has been proven to be no less effective than the intramuscular form in restoring functional, neurological and cognitive deficits in patients with acute AI. Both dosage forms have shown a comparable safety profile, are therapeutically equivalent, and can be used in clinical practice at both the hospital and outpatient stages of managing patients with acute cerebral circulatory disorders.
- 30 December 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (12) , 60-67
Therapeutic equivalence of intravenous and intramuscular dosage forms of Cortexin in ischemic strokes
Objective. Study of the therapeutic equivalence of forms for intramuscular and intravenous administration of the drug Cortexin in patients in the acute and early recovery periods of ischemic stroke (IS). Material and methods. A multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted. The study included 490 patients with acute IS, male (54.1%) and female (45.9%) aged from 30 to 80 years (average age 63.97+8.5 years), divided into 2 groups: 1 — main (Cortexin intravenous form, n=246), 2 — comparison (Cortexin intramuscular form, n=244). Patients in both groups received 2 courses of therapy lasting 10 days. In the first course: Group 1 — Cortexin 10 mg IV and placebo IM 2 times a day; Group 2 — Cortexin 10 mg IM and placebo IV 2 times a day. After 10 days, patients in both groups received a second course of therapy with Cortexin 10 mg, IM, 2 times a day, 10 days. The period of active treatment and observation for each patient was 90 days. The evaluation of the effectiveness of the studied Cortexin dosage forms was defined as the proportion of patients who reached 0—2 on the modified Rankin scale (mRS) on the 90th day of the study. Additionally, the dynamics of scores on the Stroke Scale of the National Institute of Health (NIHSS) and the Short Mental Status Assessment Scale (MMSE) were evaluated on the days of active treatment and follow-up. Safety was assessed by the frequency of adverse events (AE). Results. The proportion of patients who reached 0—2 on the mRS scale on day 90 was 93.64% and 86.50% in the groups receiving Cortexin intravenously and intramuscularly, respectively. By the end of the follow-up period, the total score on the NIHSS scale decreased by 3.93 and 3.72, respectively, in both groups. According to the MMSE scale, by the day of completion of the study, the overall dynamics of the average score in group 1 was 4.11, in the comparison group 3.88 (p=0.249). The study showed the comparable safety of the two dosage forms of Cortexin. In the main group 1, 74 AES were registered in 60 patients, in the comparison group — 51 AES in 41 people, the number of cases did not differ between the groups (p>0.05). Conclusion. The intravenous form of Cortexin administration has been proven to be no less effective than the intramuscular form in restoring functional, neurological and cognitive deficits in patients with acute AI. Both dosage forms have shown a comparable safety profile, are therapeutically equivalent, and can be used in clinical practice at both the hospital and outpatient stages of managing patients with acute cerebral circulatory disorders.
- Open Access
- 27 September 2025
- Published by Rostov State Medical University in South Russian Journal of Therapeutic Practice
- Vol. 6 (3) , 17-23
Aortic dissection presenting with neurological symptoms: prevalence, clinical features, and diagnostic challenges.
Objective: to investigate the prevalence and clinical features of aortic dissection in patients presenting with neurological symptoms. To evaluate the characteristics of the disease course and diagnosis depending on the presence of pain syndrome. Materials and methods: a retrospective cohort comparative study was conducted using the medical records of 130 patients hospitalized in the State Budgetary Healthcare Institution “Research Institute – Regional Clinical Hospital No. 1 n. a. prof. S.V. Ochapovsky” with a diagnosis of Stanford type A aortic dissection from 2020 to 2024. Patients with aortic dissection andneurological symptoms were divided into two groups: those with and without pain syndrome. A comparative analysis of risk factors, clinical manifestations, diagnostic data, treatment strategies, and outcomes was performed in both groups, with an assessment of the statistical significance of identified differences. Results: all patients had Stanford type A dissection; DeBakey type I was identified in 84 (65 %) patients, and type II in 46 (35 %). Among the 130 patients, 31 (23.8 %) presented with neurological symptoms. In 11 (35 %) of these, the typical pain syndrome was absent. Mortality among patients with neurological manifestations was 71 % (22 out of 31). Comparative analysis showed that a higher frequency of diagnostic errors was observed in the group of patients with neurological symptoms but without pain syndrome (p = 0.02). In this group, there were significantly more women (72.7 % vs. 25 %, p = 0.05), ischemic stroke developed more frequently (36.4 % vs. 5 %, p = 0.02), and a diagnosis of aortic dissection was significantly less often established during life – in 36.4 % of cases, it was confirmed only at autopsy (vs. 5 %, p = 0.02). Patients with neurological symptoms and typical pain demonstrated a higher frequency of hypotension, likely related to more severe vascular disturbances. A clinical case of a painless variant of aortic dissection, manifested by impaired consciousness and monoparesis of the arm, is presented. Conclusion: aortic dissection, especially in the presence of neurological symptoms, presents a diagnostic challenge requiring a careful approach to atypical manifestations, such as ischemic stroke. The absence of pain syndrome can complicate diagnosis and delay the initiation of treatment. Theobtained data require further research to improve diagnostic strategies, especially in cases with atypical presentations.
- 27 September 2025
- Published by Rostov State Medical University in South Russian Journal of Therapeutic Practice
- Vol. 6 (3) , 17-23
Open AccessAortic dissection presenting with neurological symptoms: prevalence, clinical features, and diagnostic challenges.
Objective: to investigate the prevalence and clinical features of aortic dissection in patients presenting with neurological symptoms. To evaluate the characteristics of the disease course and diagnosis depending on the presence of pain syndrome. Materials and methods: a retrospective cohort comparative study was conducted using the medical records of 130 patients hospitalized in the State Budgetary Healthcare Institution “Research Institute – Regional Clinical Hospital No. 1 n. a. prof. S.V. Ochapovsky” with a diagnosis of Stanford type A aortic dissection from 2020 to 2024. Patients with aortic dissection andneurological symptoms were divided into two groups: those with and without pain syndrome. A comparative analysis of risk factors, clinical manifestations, diagnostic data, treatment strategies, and outcomes was performed in both groups, with an assessment of the statistical significance of identified differences. Results: all patients had Stanford type A dissection; DeBakey type I was identified in 84 (65 %) patients, and type II in 46 (35 %). Among the 130 patients, 31 (23.8 %) presented with neurological symptoms. In 11 (35 %) of these, the typical pain syndrome was absent. Mortality among patients with neurological manifestations was 71 % (22 out of 31). Comparative analysis showed that a higher frequency of diagnostic errors was observed in the group of patients with neurological symptoms but without pain syndrome (p = 0.02). In this group, there were significantly more women (72.7 % vs. 25 %, p = 0.05), ischemic stroke developed more frequently (36.4 % vs. 5 %, p = 0.02), and a diagnosis of aortic dissection was significantly less often established during life – in 36.4 % of cases, it was confirmed only at autopsy (vs. 5 %, p = 0.02). Patients with neurological symptoms and typical pain demonstrated a higher frequency of hypotension, likely related to more severe vascular disturbances. A clinical case of a painless variant of aortic dissection, manifested by impaired consciousness and monoparesis of the arm, is presented. Conclusion: aortic dissection, especially in the presence of neurological symptoms, presents a diagnostic challenge requiring a careful approach to atypical manifestations, such as ischemic stroke. The absence of pain syndrome can complicate diagnosis and delay the initiation of treatment. Theobtained data require further research to improve diagnostic strategies, especially in cases with atypical presentations.
- 3 September 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (8) , 32-39
Results of the implementation of reperfusion technologies in ischemic stroke
Introduction. Ischemic stroke (IS) remains a serious medical and social issue due to its high prevalence, mortality, and resulting disability. Reperfusion therapy is an effective method of treating patients with IS. Objective. The aim of this study was to examine the results of implementation of reperfusion technologies for the treatment of IS in the Russian Federation. Material and methods. The analysis was based on nationwide data collected from 2015 through the first quarter of 2025. The following indicators were assessed: the proportion of IS patients admitted to stroke units within the first 4.5 hours after symptom onset; the frequency of intravenous thrombolytic therapy (IVT), including the use of telemedicine technologies for IVT administration; the rate of thrombectomy; and the hospital mortality rate from IS. The implementation of telemedicine technologies was evaluated based on the presence of teleconsulted primary stroke units (tele-PSUs) in each region and the proportion of IS patients who received IVT in tele-PSUs. Results. Over the study period, an increase was observed in the proportion of IS patients admitted within 4.5 hours of symptom onset — from 23% in 2015 to 31% in 2024. The frequency of IVT and thrombectomy procedures increased from 2% and 0.1% in 2015 to 10.2% and 2.8% in the first quarter of 2025, respectively. The rate of IVT performed in tele-PSUs in 2024 was 13.6% of IS patients admitted to tele-PSUs. The ischemic stroke mortality rate decreased from 16.8% in 2015 to 12.6% in the first quarter of 2025. Conclusions. Reperfusion therapy technologies for IS are being actively implemented across the country, significantly improving clinical approaches to stroke management. Increasing the number of reperfusion procedures will contribute to improved patient outcomes, reduced mortality, and increase the number of individuals achieving favorable recovery of neurological functions.
- 3 September 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (8) , 32-39
Results of the implementation of reperfusion technologies in ischemic stroke
Introduction. Ischemic stroke (IS) remains a serious medical and social issue due to its high prevalence, mortality, and resulting disability. Reperfusion therapy is an effective method of treating patients with IS. Objective. The aim of this study was to examine the results of implementation of reperfusion technologies for the treatment of IS in the Russian Federation. Material and methods. The analysis was based on nationwide data collected from 2015 through the first quarter of 2025. The following indicators were assessed: the proportion of IS patients admitted to stroke units within the first 4.5 hours after symptom onset; the frequency of intravenous thrombolytic therapy (IVT), including the use of telemedicine technologies for IVT administration; the rate of thrombectomy; and the hospital mortality rate from IS. The implementation of telemedicine technologies was evaluated based on the presence of teleconsulted primary stroke units (tele-PSUs) in each region and the proportion of IS patients who received IVT in tele-PSUs. Results. Over the study period, an increase was observed in the proportion of IS patients admitted within 4.5 hours of symptom onset — from 23% in 2015 to 31% in 2024. The frequency of IVT and thrombectomy procedures increased from 2% and 0.1% in 2015 to 10.2% and 2.8% in the first quarter of 2025, respectively. The rate of IVT performed in tele-PSUs in 2024 was 13.6% of IS patients admitted to tele-PSUs. The ischemic stroke mortality rate decreased from 16.8% in 2015 to 12.6% in the first quarter of 2025. Conclusions. Reperfusion therapy technologies for IS are being actively implemented across the country, significantly improving clinical approaches to stroke management. Increasing the number of reperfusion procedures will contribute to improved patient outcomes, reduced mortality, and increase the number of individuals achieving favorable recovery of neurological functions.
- 3 September 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (8) , 81-88
Increasing the accessibility of reperfusion therapy for ischemic stroke in primary vascular units using teleconsulting in the Russian Federation
Objective. To analyze the impact of primary vascular units using teleconsulting (tele-PVU) on the accessibility and quality of specialized medical care for patients with cerebrovascular accidents (CVAs). Material and methods. The study is based on data from a survey of the chief neurology consultants of 85 constituent entities of the Russian Federation and anonymized information about patients treated in tele-PVUs in 2023. The analysis included accessibility to care, the percentage of patients receiving thrombolytic therapy (TLT), and mortality. Statistical analysis was carried out using IBM SPSS Statistics v.25.0 and Microsoft Excel 2016. Results. Establishing tele-PVUs has increased the accessibility of TLT in regions with a low population density. The frequency of TLT among patients with ischemic stroke in tele-PVUs was 9.8%, exceeding the average for the Russian Federation. Tele-PVUs also contributed to a reduction in the time from the onset of stroke symptoms to the start of treatment. In several regions, there has been a significant increase in the percentage of patients receiving reperfusion therapy. However, limitations were identified regarding the lack of qualified specialists and technical conditions for telemedicine consultations. Conclusion. The establishment of new units has increased the accessibility of medical care, including reperfusion therapy for stroke patients in regions with a low population density and/or prolonged medical evacuation to the nearest specialized unit. However, for further implementation of this system, it is necessary to continue work on solving technical and organizational issues and ensure the integration of telemedicine into the existing medical system.
- 3 September 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (8) , 81-88
Increasing the accessibility of reperfusion therapy for ischemic stroke in primary vascular units using teleconsulting in the Russian Federation
Objective. To analyze the impact of primary vascular units using teleconsulting (tele-PVU) on the accessibility and quality of specialized medical care for patients with cerebrovascular accidents (CVAs). Material and methods. The study is based on data from a survey of the chief neurology consultants of 85 constituent entities of the Russian Federation and anonymized information about patients treated in tele-PVUs in 2023. The analysis included accessibility to care, the percentage of patients receiving thrombolytic therapy (TLT), and mortality. Statistical analysis was carried out using IBM SPSS Statistics v.25.0 and Microsoft Excel 2016. Results. Establishing tele-PVUs has increased the accessibility of TLT in regions with a low population density. The frequency of TLT among patients with ischemic stroke in tele-PVUs was 9.8%, exceeding the average for the Russian Federation. Tele-PVUs also contributed to a reduction in the time from the onset of stroke symptoms to the start of treatment. In several regions, there has been a significant increase in the percentage of patients receiving reperfusion therapy. However, limitations were identified regarding the lack of qualified specialists and technical conditions for telemedicine consultations. Conclusion. The establishment of new units has increased the accessibility of medical care, including reperfusion therapy for stroke patients in regions with a low population density and/or prolonged medical evacuation to the nearest specialized unit. However, for further implementation of this system, it is necessary to continue work on solving technical and organizational issues and ensure the integration of telemedicine into the existing medical system.